Logo image of ACRV

ACRIVON THERAPEUTICS INC (ACRV) Stock Fundamental Analysis

USA - NASDAQ:ACRV - US0048901096 - Common Stock

1.99 USD
-0.05 (-2.45%)
Last: 10/22/2025, 8:14:41 PM
2.01 USD
+0.02 (+1.01%)
After Hours: 10/22/2025, 8:14:41 PM
Fundamental Rating

3

ACRV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While ACRV has a great health rating, there are worries on its profitability. ACRV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACRV has reported negative net income.
In the past year ACRV has reported a negative cash flow from operations.
In the past 5 years ACRV always reported negative net income.
ACRV had a negative operating cash flow in each of the past 5 years.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ACRV has a Return On Assets (-54.20%) which is in line with its industry peers.
The Return On Equity of ACRV (-60.09%) is better than 61.80% of its industry peers.
Industry RankSector Rank
ROA -54.2%
ROE -60.09%
ROIC N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACRV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ACRV has more shares outstanding
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.64, we must say that ACRV is in the distress zone and has some risk of bankruptcy.
ACRV has a Altman-Z score of -0.64. This is comparable to the rest of the industry: ACRV outperforms 56.55% of its industry peers.
There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.64
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ACRV has a Current Ratio of 10.31. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
ACRV has a better Current ratio (10.31) than 82.02% of its industry peers.
ACRV has a Quick Ratio of 10.31. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.31, ACRV belongs to the top of the industry, outperforming 82.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.31
Quick Ratio 10.31
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.77% over the past year.
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACRV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.97% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.54%
EPS Next 2Y5.69%
EPS Next 3Y2.31%
EPS Next 5Y3.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACRV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.69%
EPS Next 3Y2.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (10/22/2025, 8:14:41 PM)

After market: 2.01 +0.02 (+1.01%)

1.99

-0.05 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners56.75%
Inst Owner Change0%
Ins Owners8.29%
Ins Owner Change-2.33%
Market Cap62.61M
Revenue(TTM)N/A
Net Income(TTM)-85958000
Analysts82.67
Price Target11.39 (472.36%)
Short Float %5.12%
Short Ratio1.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.09%
Min EPS beat(2)8.02%
Max EPS beat(2)22.15%
EPS beat(4)3
Avg EPS beat(4)10.49%
Min EPS beat(4)-0.13%
Max EPS beat(4)22.15%
EPS beat(8)6
Avg EPS beat(8)8.16%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.3%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS4.55
TBVpS4.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.2%
ROE -60.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 197.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.31
Quick Ratio 10.31
Altman-Z -0.64
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.74%
Cap/Depr(5y)383.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.77%
EPS Next Y7.54%
EPS Next 2Y5.69%
EPS Next 3Y2.31%
EPS Next 5Y3.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-96.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.85%
OCF growth 3YN/A
OCF growth 5YN/A